|
|
Volumn 12, Issue 6, 2013, Pages 419-420
|
|
What matters most in commercial success: First-in-class or best-in-class
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ARIPIPRAZOLE;
ATORVASTATIN;
CERTOLIZUMAB PEGOL;
ETANERCEPT;
FESOTERODINE;
INFLIXIMAB;
MEVINOLIN;
SEROTONIN UPTAKE INHIBITOR;
SOLIFENACIN;
TOLTERODINE;
TUMOR NECROSIS FACTOR INHIBITOR;
AUTISM;
AUTOIMMUNE DISEASE;
BIPOLAR DISORDER;
COST EFFECTIVENESS ANALYSIS;
DEPRESSION;
DRUG APPROVAL;
DRUG COST;
DRUG INFORMATION;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SURVEILLANCE PROGRAM;
DRUG USE;
ECONOMIC EVALUATION;
HUMAN;
PRIORITY JOURNAL;
PSORIASIS;
RHEUMATOID ARTHRITIS;
RISK BENEFIT ANALYSIS;
SCHIZOPHRENIA;
SHORT SURVEY;
TREATMENT INDICATION;
URINE INCONTINENCE;
ANIMAL;
DRUG DEVELOPMENT;
DRUG INDUSTRY;
METHODOLOGY;
REVIEW;
STANDARD;
TECHNOLOGY;
ANIMALS;
DRUG DISCOVERY;
DRUG INDUSTRY;
HUMANS;
TECHNOLOGY TRANSFER;
MLCS;
MLOWN;
|
|
EID: 84880672247
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4035 Document Type: Short Survey |
|
Times cited : (50)
|
|
References (0)
|
